2020 ACOG委员会意见:人乳头瘤病毒疫苗接种(No.809)

2020-08-13 美国妇产科医师学会 Obstet Gynecol . 2020 Aug;136(2):e15-e21.

2020年8月,美国妇产科医师学会(ACOG)发布了人乳头瘤病毒疫苗接种委员会意见,用以替代2017年7月份的第704号文件。人乳头状瘤病毒(HPV)疫苗可显著降低女性和男性肛门-生殖器癌和生殖器疣的

中文标题:

2020 ACOG委员会意见:人乳头瘤病毒疫苗接种(No.809)

英文标题:

Human Papillomavirus Vaccination: ACOG Committee Opinion, Number 809

发布机构:

美国妇产科医师学会

发布日期:

2020-08-13

简要介绍:

2020年8月,美国妇产科医师学会(ACOG)发布了人乳头瘤病毒疫苗接种委员会意见,用以替代2017年7月份的第704号文件。人乳头状瘤病毒(HPV)疫苗可显著降低女性和男性肛门-生殖器癌和生殖器疣的发病率。本文主要针对HPV疫苗接种的相关内容提供指导建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 ACOG委员会意见:人乳头瘤病毒疫苗接种(No.809).pdf)] GetToolGuiderByIdResponse(projectId=1, id=47dec1c0019e8934, title=2020 ACOG委员会意见:人乳头瘤病毒疫苗接种(No.809), enTitle=Human Papillomavirus Vaccination: ACOG Committee Opinion, Number 809, guiderFrom=Obstet Gynecol . 2020 Aug;136(2):e15-e21., authorId=0, author=, summary=2020年8月,美国妇产科医师学会(ACOG)发布了人乳头瘤病毒疫苗接种委员会意见,用以替代2017年7月份的第704号文件。人乳头状瘤病毒(HPV)疫苗可显著降低女性和男性肛门-生殖器癌和生殖器疣的, cover=https://img.medsci.cn/2020928/1601308423379_2020535.jpg, journalId=0, articlesId=null, associationId=357, associationName=美国妇产科医师学会, associationIntro=美国妇产科医师学会(ACOG),前身为美国妇产科学院,是一个美国妇产科妇科专业医生的专业协会。ACOG拥有超过55000名会员,其中90% 的会员是在美国经执业认证的妇产科医生。Obstetrics & Gynecology是ACOG的官方刊物。通常被称为&ldquo;绿色杂志&rdquo;。 American College of Obstetricians and Gynecologists, copyright=0, guiderPublishedTime=Thu Aug 13 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年8月,美国妇产科医师学会(ACOG)发布了人乳头瘤病毒疫苗接种委员会意见,用以替代2017年7月份的第704号文件。人乳头状瘤病毒(HPV)疫苗可显著降低女性和男性肛门-生殖器癌和生殖器疣的发病率。本文主要针对HPV疫苗接种的相关内容提供指导建议。</p> </div> </div> </div>, tagList=[TagDto(tagId=70266, tagName=人乳头瘤病毒疫苗)], categoryList=[CategoryDto(categoryId=35, categoryName=预防医学, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=70266, guiderKeyword=人乳头瘤病毒疫苗, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3029, appHits=143, showAppHits=0, pcHits=662, showPcHits=2886, likes=1, shares=8, comments=4, approvalStatus=1, publishedTime=Tue Sep 29 00:24:45 CST 2020, publishedTimeString=2020-08-13, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Sep 28 23:53:50 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 22:33:51 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 ACOG委员会意见:人乳头瘤病毒疫苗接种(No.809).pdf)])
2020 ACOG委员会意见:人乳头瘤病毒疫苗接种(No.809).pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1077991, encodeId=ca4110e799134, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/z4Az5l1QkBBEtKDRRseztsZpUicScsicF8jMvJW3tch8ibiaVTGDRWJByv1vFGQ4Pzxu7liaBPYXENY6DbD8AfRK60Q/0, createdBy=73c02203188, createdName=石虎谭, createdTime=Wed Dec 08 08:38:26 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071771, encodeId=147010e177178, content=努力学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Fri Nov 19 15:15:19 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012434, encodeId=f01210124346c, content=太棒了,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRqG3l8Ohxg7pzwwK27vkqzGeRNsrTU7H234icQhkas8uWz4rXXrek1UYqbZtUmLMmZjl2icL0ibFuvY/0, createdBy=b6842032162, createdName=5474, createdTime=Sun Aug 29 00:48:16 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900771, encodeId=4869900e7111, content=日新月异,日积月累, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=256c1518560, createdName=fanfantaoyuan, createdTime=Fri Nov 20 13:39:50 CST 2020, time=2020-11-20, status=1, ipAttribution=)]
    2021-12-08 石虎谭

    感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1077991, encodeId=ca4110e799134, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/z4Az5l1QkBBEtKDRRseztsZpUicScsicF8jMvJW3tch8ibiaVTGDRWJByv1vFGQ4Pzxu7liaBPYXENY6DbD8AfRK60Q/0, createdBy=73c02203188, createdName=石虎谭, createdTime=Wed Dec 08 08:38:26 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071771, encodeId=147010e177178, content=努力学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Fri Nov 19 15:15:19 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012434, encodeId=f01210124346c, content=太棒了,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRqG3l8Ohxg7pzwwK27vkqzGeRNsrTU7H234icQhkas8uWz4rXXrek1UYqbZtUmLMmZjl2icL0ibFuvY/0, createdBy=b6842032162, createdName=5474, createdTime=Sun Aug 29 00:48:16 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900771, encodeId=4869900e7111, content=日新月异,日积月累, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=256c1518560, createdName=fanfantaoyuan, createdTime=Fri Nov 20 13:39:50 CST 2020, time=2020-11-20, status=1, ipAttribution=)]
    2021-11-19 ms3000001592172450

    努力学习!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1077991, encodeId=ca4110e799134, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/z4Az5l1QkBBEtKDRRseztsZpUicScsicF8jMvJW3tch8ibiaVTGDRWJByv1vFGQ4Pzxu7liaBPYXENY6DbD8AfRK60Q/0, createdBy=73c02203188, createdName=石虎谭, createdTime=Wed Dec 08 08:38:26 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071771, encodeId=147010e177178, content=努力学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Fri Nov 19 15:15:19 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012434, encodeId=f01210124346c, content=太棒了,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRqG3l8Ohxg7pzwwK27vkqzGeRNsrTU7H234icQhkas8uWz4rXXrek1UYqbZtUmLMmZjl2icL0ibFuvY/0, createdBy=b6842032162, createdName=5474, createdTime=Sun Aug 29 00:48:16 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900771, encodeId=4869900e7111, content=日新月异,日积月累, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=256c1518560, createdName=fanfantaoyuan, createdTime=Fri Nov 20 13:39:50 CST 2020, time=2020-11-20, status=1, ipAttribution=)]
    2021-08-29 5474

    太棒了,学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1077991, encodeId=ca4110e799134, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/z4Az5l1QkBBEtKDRRseztsZpUicScsicF8jMvJW3tch8ibiaVTGDRWJByv1vFGQ4Pzxu7liaBPYXENY6DbD8AfRK60Q/0, createdBy=73c02203188, createdName=石虎谭, createdTime=Wed Dec 08 08:38:26 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071771, encodeId=147010e177178, content=努力学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Fri Nov 19 15:15:19 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012434, encodeId=f01210124346c, content=太棒了,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRqG3l8Ohxg7pzwwK27vkqzGeRNsrTU7H234icQhkas8uWz4rXXrek1UYqbZtUmLMmZjl2icL0ibFuvY/0, createdBy=b6842032162, createdName=5474, createdTime=Sun Aug 29 00:48:16 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900771, encodeId=4869900e7111, content=日新月异,日积月累, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=256c1518560, createdName=fanfantaoyuan, createdTime=Fri Nov 20 13:39:50 CST 2020, time=2020-11-20, status=1, ipAttribution=)]
    2020-11-20 fanfantaoyuan

    日新月异,日积月累

    0

拓展阅读

2017年WHO HPV疫苗立场文件的解读

暂未更新 · 2018-05-15

青春前期女性接种人乳头瘤病毒疫苗专家共识

中山大学附属第三医院 · 2021-09-20

2021 KSGO临床指南:人乳头瘤病毒疫苗(更新版)

韩国妇科肿瘤学会(KSGO,Korean Society of Gynecologic Oncology) · 2021-10-28

人乳头瘤病毒疫苗临床应用中国专家共识(2021年版)解读

华中科技大学同济医学院附属同济医院妇产科 · 2022-12-15